Cat. No. 3967
Chemical Name: 2-Chloro-N-[1-[(2R)-2,3-dihydroxypr
Biological ActivityAllosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239. PMID: 17934512.
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775. PMID: 17016495.
If you know of a relevant reference for GPi 688 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GPi 688 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GPi 688, supplier, GPi688, glycogen, phosphorylase, inhibitors, hyperglycaemia, hyperglycemia, inhibits, astrazeneca, Tocris Bioscience, Phosphorylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Highly potent and SAM-competitive EZH2 inhibitorGSK 591 dihydrochloride
Potent and selective PRMT5 inhibitorTP 064
Potent and selective PRMT 4 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.